Feasibility of Emotion Regulation Group Therapy for Adolescent Self-Harm (ERGT-A)

March 4, 2024 updated by: Hanna Sahlin, Karolinska Institutet

Can a Brief Emotion Regulation Group Therapy Help Adolescents With Deliberate Self-Harm? A Feasibility Study and a Qualitative Interview Study

Deliberate self-harm (DSH) is a prevalent behaviour among adolescents but there is no current recommendation for an efficacious treatment. Emotion regulation group therapy (ERGT) is a brief treatment for DSH with a well-documented utility and feasibility in the adult population, and an adapted version for adolescents may provide equal benefits for adolescents, provided adjustments to prevent or decrease social contagion are present.

A quantitative feasibility open trial (N=20) followed up by a qualitative interview study will examine the feasibility, acceptability and preliminary effect of ERGT for adolescents.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

Deliberate self-harm (DSH) is a prevalent behaviour among adolescents but there is no current recommendation for an efficacious treatment. Emotion regulation group therapy (ERGT) is a brief treatment for DSH with a well-documented utility and feasibility in the adult population, and an adapted version for adolescents may provide equal benefits for adolescents, provided adjustments to prevent or decrease social contagion are present. Adaptations to ERGT will result in a 12 session long treatment for adolescents Emotion regulation group therapy for Adolescents (ERGT-A). A parallel parent group focused on strengthening parental skills will be given alongside ERGT-A (5 sessions)

Method: A quantitative feasibility open trial (N=20) with pre, post and 1 month follow-up assessments will examine the feasibility, acceptability and preliminary effect of ERGT for adolescents.

Feasibility measures include recruitment rate, proportion beginning treatment, attrition, treatment credibility and satisfaction, negative effects, and alliance.

Preliminary effects measures include DSH, emotion regulation ability, anxiety and depression.

Method: A qualitative interview study. Using thematic analysis to explore participants' experience of ERGT-A and parent group

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Spånga
      • Stockholm, Spånga, Sweden, 16374

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. 13-17 years of age;
  2. having engaged in deliberate self-harm (DSH)-behaviours ≥ 5 times the last year;
  3. having engaged in ≥1 DSH episode during the past month;
  4. having ongoing psychiatric treatment in the community;
  5. having at least one caregiver or other significant adult, committed to participate in the parent program; and
  6. stability of psychotropic medications

Exclusion Criteria:

  1. a diagnosis of psychotic, bipolar I disorder or severe social anxiety disorder (SAD);
  2. ongoing substance dependence;
  3. the presence of co-occurring psychiatric disorders that require immediate treatment;
  4. having an autism spectrum disorder together with borderline intellectual disability or having an intellectual disability;
  5. insufficient understanding of the Swedish language

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: ERGT-A
12 session emotion regulation treatment in group format. Psychoeducation and homework assignments. Subjects taught are the function of deliberate self-harm (DSH), functionality of emotions, negative consequences of emotional avoidance, non-avoidant emotion regulation.
Emotion regulation group therapy for adolescents

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility measure, recruitment rate
Time Frame: through study completion, an average of 1 year
Recruitment rate
through study completion, an average of 1 year
Feasibility measures, proportion included
Time Frame: through study completion, an average of 1 year
Proportion of participants invited to participate who accepts and is included (higher = better, min 0%- max 100%)
through study completion, an average of 1 year
Feasibility measures, compliance
Time Frame: Pre-treatment to post-treatment (End of treatment, EOT) (12 weeks)
Compliance, no of sessions attended (>50%), (higher = better, min 0-max 10)
Pre-treatment to post-treatment (End of treatment, EOT) (12 weeks)
Feasibility measures, attrition
Time Frame: Pre-treatment to post-treatment EOT (12 weeks)
Attrition, percent of included participants who drops out of treatment (lower = better, min 0%- max 100%)
Pre-treatment to post-treatment EOT (12 weeks)
Feasibility measures, client satisfaction
Time Frame: at post-treatment EOT (12 weeks)
Mean score on Client satisfaction questionnaire> 25 (higher= better, min 8-max 32)
at post-treatment EOT (12 weeks)
Feasibility measures, negative effects of treatment
Time Frame: at post-treatment EOT (12 weeks)
Low rating on Negative effects Questionnaire (lower= better, min 0-max 20)
at post-treatment EOT (12 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Preliminary effect, self harm frequency EOT
Time Frame: Pre-treatment to post-treatment (EOT) (12 weeks)
Mean Deliberate self-harm frequency at post-treatment (min 0-max 100, lower=better)
Pre-treatment to post-treatment (EOT) (12 weeks)
Preliminary effect, self harm frequency 1MFU
Time Frame: Post-treatment (EOT) to follow-up (4 weeks)
Mean Deliberate self-harm frequency at post-treatment and 1MFU lower than at post-treatment (min 0-max 100, lower=better)
Post-treatment (EOT) to follow-up (4 weeks)
Preliminary effect, emotion dysregulation EOT
Time Frame: Pre-treatment to post-treatment (EOT) (12 weeks)
Mean difficulty in emotion regulation rating (DERS-16) at post-treatment lower than at pre-treatment (min 16, max 80, lower=better)
Pre-treatment to post-treatment (EOT) (12 weeks)
Preliminary effect, emotion dysregulation 1MFU
Time Frame: Post-treatment (EOT) to follow-up (4 weeks)
Mean difficulty in emotion regulation rating (DERS-16) at 1MFU lower than at post-treatment (min 16, max 80, lower=better)
Post-treatment (EOT) to follow-up (4 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hanna Sahlin, PhD, Karolinska Institutet

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 10, 2023

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

June 30, 2025

Study Registration Dates

First Submitted

January 29, 2024

First Submitted That Met QC Criteria

March 4, 2024

First Posted (Actual)

March 7, 2024

Study Record Updates

Last Update Posted (Actual)

March 7, 2024

Last Update Submitted That Met QC Criteria

March 4, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2023-04909-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Emotion Regulation

Clinical Trials on ERGT-A

3
Subscribe